David S. Viswanatha, M.D., explains how Mayo Clinic Laboratories' new assay provides rapid, definitive diagnosis of VEXAS, a recently identified syndrome affecting older men. Early diagnosis is key to managing the condition, which severely impacts multiple organs and blood.

(00:31)
 Could you please provide a little bit about yourself and your background?

(01:30)
 Would you please share a brief overview of the UBA1Q assay?

(02:13)
 Would you provide an overview of VEXAS syndrome?

(05:30)
 When is this testing recommended during care for patients who have a suspected inflammatory condition or VEXAS syndrome?

(06:38)
 What advantage does this assay provide over other methodologies?

(10:13)
 Could you share further why diagnosis is so important for these patients?

(12:40)
 Is there anything else you'd like to comment about the assay?